Manuscript Detail

View Revisions

Sonuga-Barke, E. J., Barton, J., Daley, D., Hutchings, J., Maishman, T., Raftery, J., Stanton, L., Laver-Bradbury, C., Chorozoglou, M., Coghill, D., Little, L., Ruddock, M., Radford, M., Yao, G.L., Lee, L., Gould, L., Shipway, L., Markomichali, P., McGuirk, J., Lowe, M., Perez, E., Lockwood, J., & Thompson, M. J. (2018). A comparison of the clinical effectiveness and cost of specialised individually delivered parent training for preschool attention-deficit/hyperactivity disorder and a generic, group-based programme: a multi-centre, randomised controlled trial of the New Forest Parenting Programme versus Incredible Years. European Child & Adolescent Psychiatry, 27(6), 797-809. Study 1. 

Manuscript screening details
Screening decision Screening conclusion HomVEE procedures and standards version
Passes screens Eligible for review Version 2
Study design details
Rating Design Attrition Baseline equivalence Compromised randomization Confounding factors Valid, reliable measure(s)
Low Randomized controlled trial Not applicable

Not applicable

Not applicable

No

Measure validity and reliability is not assessed for findings that receive a low evidence rating; all findings in this manuscript received a low rating.

Notes:

The study authors used multiple imputation, which is an acceptable missing data approach under HomVEE standards. However, HomVEE was not able to confirm that the multiple imputation approach the authors used met all requirements for such an approach under Version 2 of the HomVEE standards. The manuscript describes a randomized controlled trial that compared NFPP to two eligible comparison conditions. This page reports findings from the comparison of NFPP outcomes to those of Incredible Years. The other comparison is reported under Sonuga-Barke et al., 2018 (Study 2).

Study Registration:

Clinicaltrials.gov Identifier: None found. SocialScienceRegistry.org Identifier: None found. Registry of Efficacy and Effectiveness Studies Identifier: None found. Study registration was assessed by HomVEE for Clinicaltrials.gov beginning with the 2014 review, and for other registries beginning with the 2021 review.